Monitoring
Serial FLC ascertainment should be routinely performed in patients with AL amyloidosis and multiple myeloma patients with oligosecretory disease. It should also be done in all patients who have achieved a complete response to determine whether they have attained a stringent complete response.
Other guidelines for the use of serum free light chain measurement in the management of AL amyloidosis, plasmacytoma and the comparison of treatment responses in clinical trials have also been published.
Technical/clinical reviews of serum free light-chain assays have recently been written by Pratt and Jagannath.
Read more about this topic: Serum Free Light Chain Measurement, Guidelines